ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Economic Impact of Donor Hepatitis C Kidney Transplantation: A Medicare Cost Analysis

K. Lentine1, M. Schnitzler2, T. Alhamad3, H. Xiao2, H. Randall2, J. Wellen2, B. Kasiske4, G. Hess5, D. Axelrod6

1Saint Louis University Medical Center, St. Louis, MO, 2Saint Louis Univ, St. Louis, MO, 3Washington Univ, St. Louis, MO, 4SRTR, Minneapolis, MN, 5Univ of Pennsylvania, Philadelphia, PA, 6Univ of Iowa, Iowa City, IA

Meeting: 2019 American Transplant Congress

Abstract number: 473

Keywords: Economics, Hepatitis C, Kidney transplantation, Medicare

Session Information

Date: Tuesday, June 4, 2019

Session Name: Concurrent Session: Non-Organ Specific: Economics & Ethics

Session Time: 2:30pm-4:00pm

 Presentation Time: 2:30pm-2:42pm

Location: Room 309

Related Abstracts
  • Use of Hepatitis-C Treatments after Kidney Transplantation: Impact of the Direct-Acting Antiviral Era
  • Cost Effectiveness of Hepatitis C Positive Donor Kidney Transplantation for Hepatitis C Negative Recipients with Concomitant Direct-Acting Anti-Viral Therapy

*Purpose: In the era of highly effective direct-acting antiviral agents (DAAs), kidney transplant (KT) from Hepatitis C virus (HCV)-positive donors is increasingly considered as an option for expanding the organ supply, including for HCV-naïve recipients. However, the economic implications of this practice are not well defined.

*Methods: This study was performed from the perspective of Medicare as payer for KT services. We examined the economic impact of donor (D) HCV serostatus using a linkage of SRTR data to Medicare Part A/B payments among Medicare-insured KT recipients (n=20,188) in the DAA era (1/1/2014-12/31/2016). Medicare payments were examined during the transplant event, from discharge to first anniversary (year 1), and in years 2 and 3 posttransplant. Marginal economic impacts were estimated by robust regression, including adjustment for other baseline donor and recipient factors captured in the registry.

*Results: Categorized by HCV serostatus, KT in the study period were 2.2% D+, 3.1% D-/R+ and 94.4% D-/R-. Mean payments for HCV D+ vs. D-/R- KT were $36,091 vs $33,677 during the transplant hospitalization. During the remainder of year 1, average Medicare payments were $55,105 vs $52,347 for HCV D+ vs D-/R- KT, respectively. After multivariate adjustment, HCV D+ KT was associated with $3387 (P=0.004) higher costs during the transplant episode, and $2478 (P<0.0001) and $1023 (P=0.03) higher adjusted Medicare expenditures in year 1 and year 2, respectively, exclusive of pharmaceutical care. By year 3, adjusted payments did not differ by donor HCV serostatus.

*Conclusions: D+ serostatus is associated with higher costs of early care after KT, independent of pharmaceuticals. Future work should examine comprehensive cost effectiveness, including benefits of reduced dialysis time, medication costs, and clinical and cost impact of more complex care.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Lentine K, Schnitzler M, Alhamad T, Xiao H, Randall H, Wellen J, Kasiske B, Hess G, Axelrod D. Economic Impact of Donor Hepatitis C Kidney Transplantation: A Medicare Cost Analysis [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/economic-impact-of-donor-hepatitis-c-kidney-transplantation-a-medicare-cost-analysis/. Accessed April 17, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.